More about
Huntington's Diseases
News
September 14, 2023
1 min read
Save
FDA accepts new drug application for sprinkle form of Ingrezza capsules
The FDA has accepted a new drug application from Neurocrine Biosciences Inc. for its novel granule formulation of oral Ingrezza capsules, for those with tardive dyskinesia or chorea associated with Huntington’s disease.